Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice

COVID-19 is an immune-mediated inflammatory disease caused by SARS-CoV-2 infection, the combination of anti-inflammatory and antiviral therapy is predicted to provide clinical benefits. We recently demonstrated that mast cells (MCs) are an essential mediator of SARS-CoV-2-initiated hyperinflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Meng-Li, Liu, Feng-Liang, Sun, Jing, Li, Xin, Qin, Jian-Ru, Yan, Qi-Hong, Jin, Xia, Chen, Xin-Wen, Zheng, Yong-Tang, Zhao, Jin-Cun, Wang, Jian-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113965/
https://www.ncbi.nlm.nih.gov/pubmed/35503561
http://dx.doi.org/10.24272/j.issn.2095-8137.2021.469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113965/
https://www.ncbi.nlm.nih.gov/pubmed/35503561
http://dx.doi.org/10.24272/j.issn.2095-8137.2021.469

Ejemplares similares